Establishment of a Comprehensive Intervention Program to Extend Healthy Life Expectancy and Improve Quality of Life in Elderly Patients with Type 2 Diabetes - Establishment of a Comprehensive Intervention Program to Extend Healthy Life Expectancy and Improve Quality of Life in Elderly Patients with Type 2 Diabetes

Gifu University Hospital, Diabetes Metaphysical Internal Medicine / Immunology & Endocrinology0 sites22 target enrollmentAugust 31, 2021

Overview

Phase: N/A
Intervention: Not specified
Conditions: Type 2 diabetes
Sponsor: Gifu University Hospital, Diabetes Metaphysical Internal Medicine / Immunology & Endocrinology
Enrollment: 22
Status: Completed
Last Updated: last year

No summary available.

Registry

who.int

Start Date

August 31, 2021

End Date

March 31, 2027

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Gifu University Hospital, Diabetes Metaphysical Internal Medicine / Immunology & Endocrinology

•Patients who fall into any of the following criteria are excluded from participating in the study; 1\) Patients with diabetes other than type 2 diabetes. 2\) Patients with a history of hospitalization for any disease in the past 6 months. 3\) Patients with diabetic retinopathy (patients with proliferative retinopathy, vitreous hemorrhage, or other severe clinical abnormality). 4\) Patients with mental disorders. 5\) Patients with a habit of consuming alcohol more than 5 days a week. 6\) Patients whose latest hemoglobin before giving their consent is less than 11 g/dl. 7\) Patients with severe renal dysfunction (eGFR of less than 30 mL/min/1\.73m2\). 8\) Patients with severe hepatic dysfunction (any of ALT, AST or ALP is more than 3 times of Upper Limit of Normal. 9\) Patients with acute diabetic complications or severe infections. 10\) Patients who have history of malignant tumor within 5 years before giving their consent. 11\) Patients with joint symptoms that interfere with daily life. 12\) Patients who have difficulty following the instructions of the principal investigator or subinvestigators. 13\) Patients who are participating in other clinical studies. 14\) Patients with other conditions that the responsible investigator or subinvestigators think inappropriate to participate in the study.